1. SupportingIrish patientsand theIrish economyValue of Medicines and VaccinesDelivering value to the Irish health services and the Irish economyDavid Gallagher, IPHA President…

1. Newsletter 10 30 June 2014_Quarterly newsletter 022014 NPL 193RD NPL MEETING 3rd International Workshop on the non-performing loans sector SEPTEMBER 2014 Domestic vsInternational…

GREECE Memorandum of Understanding on Specific Economic Policy Conditionality Draft of 9 February 2012 The disbursements of financial assistance to Greece, by the European…

Incorporating life-cycle price modelling into pharmaceutical cost-effectiveness evaluations Research Paper 15/02 August 2015 Michele Pistollato Incorporating life-cycle price…

Slide 1 Can We Keep Pharmaceutical Costs Affordable and New Medicines Development Viable? A P.B.S. Perspective Can We Keep Pharmaceutical Costs Affordable and New Medicines…

Slide 1 Presentation by Ganesh Nayak, COO and Executive Director, Zydus Cadila Slide 2 Challenges for healthcare system Expectation of high quality healthcare –Facilities…

Slide 1 Pharmacoepidemiology: Past, present and future Kathleen Bennett, PhD Department of Pharmacology & Therapeutics, Trinity College Dublin [email protected] 3 rd Sept…

Slide 1 Improving access to generic & biosimilar medicines in Bulgaria and in the EU 1 Adrian van den Hoven Director General EGA – European Generic medicines Associations…

Slide 1 Value based contracting for medicine: the experiences of South Korea Eun Young Bae Nov5, 2013 Gyeongsang National University Slide 2 Contents Background Reimbursement…

Evidence-based Medicine and Disease Management: Strategic Context, Emerging Implications Paul H. Keckley, Ph.D. Associate Professor, Vanderbilt School of Medicine, Nashville,…